News and Trends 23 Jun 2023 SandboxAQ launches new division to boost drug development After several years of stealth development, SandboxAQ has announced its bio-pharma molecular simulation division, AQBioSim, and some of its customers. The division is helping bio-pharma and research institutions achieve breakthroughs in treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. The company is currently working with biopharma companies and university research labs, including AstraZeneca, Sanofi and […] June 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2023 NodThera announces positive inflammatory disease data NodThera has announced positive data from first-in-human studies of its lead therapeutic candidates, NT-0249 and NT-0796. In the studies, both candidates were shown to clearly inhibit the NLRP3 inflammasome, a highly validated drug target that plays a pivotal role in controlling inflammatory diseases. The differentiated design characteristics of each candidate enabled them to penetrate different […] June 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 21 Apr 2023 Gut microbiome: a promising target for Parkinson’s Home to around a thousand microbial species, the gut’s role in nutrient and drug metabolism is pivotal for immune function. As trillions of bacteria that thrive in the gastrointestinal system aid in the metabolic activity, the gut microbiome can also be influential in therapeutic research for an array of diseases, including Parkinson’s. And of late, […] April 21, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 13 Apr 2023 Parkinson’s cure ‘inevitable’ after biomarker breakthrough The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has announced what it says is the ‘most significant breakthrough yet’ in the search for a Parkinson’s biomarker: a biological test for Parkinson’s disease. The test demonstrates high diagnostic accuracy, differentiates molecular subtypes and detects disease in individuals before cardinal movement symptoms arise. A paper on […] April 13, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 12 Apr 2023 6 new vaccines being developed for difficult-to-treat diseases There are several promising new vaccine candidates being developed for complex diseases that historically have been extremely difficult to find treatments and cures for. The development of these new vaccines could eventually lead to breakthrough treatments for diseases such as Alzheimer’s disease, HIV, Parkinson’s disease, Lyme disease, and breast cancer. According to the World Health […] April 12, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 11 Apr 2023 Is a vaccine for Parkinson’s disease possible? Finding a truly effective treatment for Parkinson’s disease – that goes beyond simply managing symptoms – has long been a challenging task and, to this day, there are no available therapeutic options that can effectively slow or stop the underlying disease. However, research and trials to find treatments are ongoing and, as World Parkinson’s Day […] April 11, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 8 Mar 2023 The challenges of tackling dementia in women Dr Andrea Pfeifer, chief executive officer of AC Immune SA, talks to Labiotech about dementia research, and how dementia affects women. She also addresses how vital research is when it comes to addressing women’s health. Dementia is a leading cause of death in women, but it doesn’t get the attention of other diseases, such as […] March 8, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 2 Mar 2023 Could new dementia treatment come from intestinal bacteria discovery? Dementia with Lewy bodies (DLB), one of the most common forms of dementia, has no cure. Previous studies suggested that gut bacteria play a role in Parkinson’s disease, another neurodegenerative disorder, but the bacteria involved in dementia with Lewy bodies had not been identified. Now, a group led by researchers at the Nagoya University Graduate […] March 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has issued a call for multinational research on large scale analysis of OMICS data for drug-target finding in neurodegenerative diseases. Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 50 million people with Alzheimer’s […] January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: IRLAB CEO Richard Godfrey IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson’s disease. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to […] December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2022 BrainEver and 3P Biopharmaceuticals developing drug with hopes to cure ALS 3P BioPharmaceuticals and BrainEver are to collaborate on developing hEng1, a recombinant homeoprotein, to treat pathologies such as amyotrophic lateral sclerosis (ALS) or Parkinson’s disease. 3P BioPharmaceuticals is a contract development and manufacturing organization (CDMO) specializing in the process development and cGMP manufacturing of biological products, and BrainEver is a French biotechnology company focusing on […] November 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS NRG Therapeutics, Ltd. has closed a £16 million ($18.2 million) series A financing. The funding was led by Omega Funds and joined by additional new investor Brandon Capital and founding investor Parkinson’s Virtual Biotech. NRG Therapeutics is using mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email